Myeloid antigen co-expression in childhood acute lymphoblastic leukaemia: Relationship with in vitro drug resistance

British Journal of Haematology

Volumn 105, Issue 4, 1999, Pages 876-882

  Den Boer, M L ^a,c   Kapaun, P ^b   Pieters, R ^a   Kazemier, K M ^a   Janka Schaub, G E ^b   Veerman, A J P ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

ALL; Drug resistance; LRP; MRP; Myeloid antigen; P gp

Indexed keywords

ANTILEUKEMIC AGENT; ASPARAGINASE; CD33 ANTIGEN; CELL ANTIGEN; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; GLUCOCORTICOID; GLYCOPROTEIN P; IDARUBICIN; IFOSFAMIDE; MERCAPTOPURINE; MICROSOMAL AMINOPEPTIDASE; MITOXANTRONE; TENIPOSIDE; TIOGUANINE; VINCRISTINE; VINCRISTINE SULFATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANTIGEN EXPRESSION; ARTICLE; CANCER RESISTANCE; CHILD; CONTROLLED STUDY; DRUG UPTAKE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INFANT; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ANTIGENS, CD; ANTIGENS, CD13; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; DAUNORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED;

EID: 0032987948     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1999.01440.x     Document Type: Article

References (43)

1. Basso, G., Putti, M.C., Cantú-Rajnoldi, A., Saitta, M., Santostasi, T., Santoro, N., Lippi, A., Comelli, A., Felici, L., Favre, C., Russo Mancuso, G., Guglielmi, C., Paolucci, P., Biondi, A., Rondelli, R. & Pession, A. (1992) The immunophenotype in infant acute lymphoblastic leukaemia: correlation with clinical outcome: an Italian multicentre study (AIEOP). British Journal of Haematology, 81, 184-191.
2. Beck, J., Handgretinger, R., Dopfer, R., Klingebiel, T., Niethammer, D. & Gekeler, V. (1995) Expression of mdr1, mrp, topoisomerase IIα/β, and cyclln A in primary or relapsed states of acute lymphoblastic leukaemias. British Journal of Haematology, 89, 356-363.
3. Cantú-Rajnoldi, A., Putti, C., Saitta, M., Granchi, D., Foà, R., Schirò, R., Castagni, M., Valeggio, C., Jankovic, M., Miniero, R., Paolucci, P. & Basso, G. (1991) Co-expression of myeloid antigens in childhood acute lymphoblastic leukaemia: relationship with the stage of differentiation and clinical outcome. British Journal of Haematology, 79, 40-43.
4. Den Boer, M.L., Pieters, R., Kazemier, K.M., Rottier, M.M.A., Scheper, R.J., Janka, G. & Veerman, A.J.P. (1997a) LRP expression and intracellular DNR concentration are related to drug resistance in childhood leukemia. Proceedings of the American Association for Cancer Research, 38, 442.
5. Den Boer, M.L., Pieters, R., Kazemier, K.M., Rottier, M.M.A., Zwaan, C.M., Kaspers, G.J.L., Janka-Schaub, G., Henze, G., Creutzig, U., Scheper, R.J. & Veerman, A.J.P. (1998a) Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood, 91, 2092-2098.
6. Den Boer, M.L., Pieters, R. & Veerman, A.J.P. (1998b) Mechanisms of cellular anthracycline resistance in childhood acute leukemia. Leukemia, 12, 1657-1670.
7. Den Boer, M.L., Zwaan, C.M., Pieters, R., Kazemier, K.M., Rottier, M.M.A., Flens, M.J., Scheper, R.J. & Veerman, A.J.P. (1997b) Optimal immunocytochemical and flow cytometric detection of P-gp, MRP and LRP in childhood acute lymphoblastic leukemia. Leukemia, 11, 1078-1085.
8. Drexler, H.G., Thiel, E. & Ludwig, W.D. (1991) Review of the incidence and clinical relevance of myeloid antigen-positive acute lymphoblastic leukemia. Leukemia, 5, 637-645.
9. Fink, F.M., Köller, U., Mayer, H., Haas, O.A., Grümayer-Panzer, E.R., Urban, C., Dengg, K., Mutz, I., Tüchler, H., Gatterer-Menz, I., Knapp, W. & Gadner, H. (1993) Prognostic significance of myeloid-associated antigen expression on blast cells in children with acute lymphoblastic leukemia. Medical and Pediatric Oncology, 21, 340-346.
10. Flens, M.J., Izquierdo, M.A., Scheffer, G.L., Fritz, J.M., Meijer, C.J.L.M., Scheper, R.J. & Zaman, G.J.R. (1994) Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Research, 54, 4557-4563.
11. Germann, U.A. (1996) P-glycoprotein: a mediator of multidrug resistance in tumour cells. European Journal of Cancer, 32A, 927-944.
12. Goasguen, J.E., Dossot, J.M., Pardel, O., Le Mee, F., Le Gall, E., Leblay, R., LePrise, P.Y., Chapereon, J. & Fauchet, R. (1993) Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications, Blood, 81, 2394-2398.
13. Greaves, M.F., Chan, L.C., Furley, A.J.W. Watt, S.M. & Molgaard, H.V. (1986) Lineage promiscuity in hemopoietic differentiation and leukemia. Blood, 67, 1-11.
14. Howard, M.R., Thomas, L. & Reid, M.M. (1994) Variable detection of myeloid antigens in childhood acute lymphoblastic leukaemia. Journal of Clinical Pathology, 47, 1006-1009.
15. Ivy, P., Sather, H.N., Hammond, G.D. & Reaman, G.H. (1993) The prognostic significance of MDR1 gene expression at diagnosis in childhood acute lymphoblastic leukemia (ALL). Pediatric Research, 13, 141A.
16. Ivy, S.P., Olshefski, R.S., Taylor, B.J., Patel, K.M. & Reaman, G.H. (1996) Correlation of P-glycoprotein expression and function in childhood acute leukemia: a Children's Cancer Group study. Blood, 88, 309-318.
17. Izquierdo, M.A., Scheffer, C.L., Flens, M.J., Schroeijers, A.B., Van der Valk, P. & Scheper, R.J. (1996) Major vault protein LRP-related multidrug resistance. European Journal of Cancer, 32A, 979-984.
18. Kaspers, G.J.L., Kardos, G., Pieters, R., Van Zantwijk, C.H., Klumper, E., Hählen, K., De Waal, F.C., Van Wering, E.R. & Veerman, A.J.P. (1994a) Different cellular drug resistance profiles in childhood lymphoblastic and non-lymphoblastic leukemia: a preliminary report. Leukemia, 8, 1224-1229.
19. Kaspers, G.J.L., Pieters, R., Van Zantwijk, C.H., De Laat, P.A.J.M., De Waal, F.C., Van Wering, E.R. & Veerman, A.J.P. (1991) In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells from bone marrow and peripheral blood. British Journal of Cancer, 64, 469-474.
20. Kaspers, G.J.L., Pieters, R., Van Zantwijk, C.H., Van Wering, E.R. & Veerman, A.J.P. (1995a) Clinical and cell biological features related to cellular drug resistance of childhood acute lymphoblastic leukemia cells. Leukemia and Lymphoma, 19, 407-416.
21. Kaspers, G.J.L., Smets, L.A., Pieters, R., Van Zantwijk, C.H., Van Wering, E.R. & Veerman, A.J.P. (1995b) Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood, 85, 751-756.
22. Kaspers, G.J.L., Veerman, A.J.P., Pieters, R., Broekema, G.J., Huismans, D.R., Kazemier, K.M., Loonen, A.H., Rottier, M.M.A., Van Zantwijk, C.H., Hählen, K. & Van Wering, E.R. (1994b) Mononuclear cells contaminating leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay. British Journal of Cancer, 70, 1047-1052.
23. Kaspers, G.J.L., Veerman, A.J.P., Pieters, R., Van Zantwijk, C.H., Smets, L.A., Van Wering, E.R. & Van der Does-van den Berg, A. (1997) In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood, 90, 2723-2729.
24. Kingreen, D., Sperling, C., Notter, M., Schmidt, C., Diddens, H., Riehm, H., Thiel, E. & Ludwig, W.D. (1992) Sequential analysis of P-glycoprotein expression in childhood acute lymphoblastic leukemia. Hematology and Blood Transfusion, 34, 23-28.
25. Klumper, E., Pieters, R., Veerman, A.J.P., Huismans, D.R., Loonen, A.H., Hählen, K., Kaspers, G.J.L., Van Wering, E.R., Hartmann, R. & Henze, G. (1995) In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood, 86, 3861-3868.
26. Kurec, A.S., Belair, P., Stefanu, C., Barrett, D.M., Dubowy, R.L. & Davey, F.R. (1991) Significance of aberrant immunophenotypes in childhood acute lymphoid leukemia. Cancer, 67, 3081-3086.
27. Loe, D.W., Deeley, R.G. & Cole, S.P.C. (1996) Biology of the multidrug resistance-associated protein, MRP. European Journal of Cancer, 32A, 945-957.
28. Pieters, R., Den Boer, M.L., Durian, M., Janka, G., Schmiegelow, K., Kaspers, G.J.L., Van Wering, E.R. & Veerman, A.J.P. (1998) Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia: implications for treatment of infants. Leukemia, 12, 1344-1348.
29. Pieters, R., Kaspers, G.J.L., Van Wering, E.R., Huismans, D.R., Loonen, A.H., Hählen, K. & Veerman, A.J.P. (1993) Cellular drug resistance profiles that might explain the prognostic value of immunophenotype and age in childhood acute lymphoblastic leukemia. Leukemia, 7, 392-397.
30. Pieters, R., Klumper, E., Kaspers, G.J.L. & Veerman, A.J.P. (1997) Everything you always wanted to know about cellular drug resistance in childhood acute lymphoblastic leukemia. Critical Reviews in Oncology/Hematology, 25, 11-26.
31. Pieters, R., Loonen, A.H., Huismans, D.R., Broekema, G.J., Dirven, M.W.J., Heyenbrok, M.W., Hählen, K. & Veerman, A.J.P. (1990) In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood, 76, 2327-2336.
32. Pui, C.H. (1995) Childhood leukemias. New England Journal of Medicine, 332, 1618-1630.
33. Pui, C.H., Behm, E.G., Singh, B., Rivera, G.K., Schell, M.J., Roberts, W.M., Crist, W.M. & Mirro, J. (1990) Myeloid-associated antigen expression lacks prognostic value in childhood acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. Blood, 75, 198-202.
34. Pui, C.H., Raimondi, S.C., Head, D.R., Schell, M.J., Rivera, G.K., Mirro, J., Crist, W.M. & Behm, E.G. (1991) Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. Blood, 78, 1327-1337.
35. Putti, M.C., Basso, G., Cocito, M.G., Biondi, A., Conter, V., Arico, M., Testi, A.M., Santoro, N., Barisone, E., Rondelli, R., Rizzari, R., Pession, A., Zanesco, L. & Masera, G. (1997) Expression of mycloid antigens in childhood acute lymphoblastic leukemia (ALL) has no prognostic impact in BFM-oriented AIEDP ALL 88 and 91 studies. Medical and Pediatric Oncology 29, 317.
36. Reiter, A., Schrappe, M., Ludwig, W.D., Hiddemann, W., Sauter, S., Henze, G., Zimmermann, M., Lampert, F., Havers, W., Niethammer, D., Odenwald, E., Ritter, J., Mann, G., Welte, K., Gadner, H. & Riehm, H. (1994) Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: results and conclusions of the multicenter trial ALL-BFM 86. Blood, 84, 3122-3133.
37. Sauerbrey, A., Zintl, F. & Volm, M. (1994) P-glycoprotein and glutathione S-tranferase π in childhood acute lymphoblastic leukaemia. British Journal of Cancer, 70, 1144-1149.
38. Scheffer, G.L., Wijngaard, P.L.J., Flens, M.J., Izquierdo, M.A., Slovak, M.L., Pinedo, H.M., Meijer, C.J.L.M., Clevers, H.C. & Scheper, R.J. (1995) The drug resistance-related protein LRP is the human major vault protein. Nature Medicine, 1, 578-582.
39. Scheper, R.J., Broxterman, H.J., Scheffer, G.L., Kaaijk, P., Dalton, W.S., Van Heijningen, T.H.M., Van Kalken, C.K., Slovak, M.L., De Vries, E.G.E., Van der Valk, P., Meijer, C.J.L.M. & Pinedo, H.M. (1993) Overexpression of a Mr 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Research, 53, 1475-1479.
40. Smith, L.J., Curtis, J.E., Messner, H.A., Senn, J.S., Furthmayr, H. & McCulloch, E.A. (1983) Lineage infidelity in acute leukemia. Blood, 61, 1138-1145.
41. Trueworthy, R., Shuster, J., Look, T., Crist, W., Borowitz, M., Carroll, A., Frankel, L., Harris, M., Wagner, H., Haggard, M., Mosijczuk, A., Pullen, J., Steuber, P. & Land, V. (1992) Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group study. Journal of Clinical Oncology, 10, 606-613.
42. Uckun, F.M., Sather, H.N., Gaynon, P.S., Arthur, D.C., Trigg, M.E., Tubergen, D.G., Nachman, J., Steinherz, P.G., Sensel, M.G. & Reaman, G.H. (1997) Clinical features and treatment outcome of children wit myeloid antigen positive acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood, 90, 28-35.
43. Wiersma, S.R., Ortega, J., Sobel, E. & Weinberg, K.I. (1991) Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood. New England Journal of Medicine, 324, 800-808.